Health related Quality of Life over time in German sarcoma patients. An analysis of associated factors - results of the PROSa study

Autor: Martin Eichler, Leopold Hentschel, Susanne Singer, Beate Hornemann, Stephan Richter, Christine Hofbauer, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Jens Jakob, Robert Grützmann, Stephen Fung, Eva Wardelmann, Karin Arndt, Kerstin Hermes-Moll, Olaf Schoffer, Marius Fried, Helena K. Jambor, Jürgen Weitz, Klaus-Dieter Schaser, Martin Bornhäuser, Jochen Schmitt, Markus K. Schuler

Publikováno v: Frontiers in Endocrinology, Vol 14 (2023)

IntroductionSarcomas are rare cancers and very heterogeneous in their location, histological subtype, and treatment. Health-Related Quality of Life (HRQoL) of sarcoma patients has rarely been investigated in longitudinal studies.MethodsHere, we asses

Externí odkaz: https://doaj.org/article/b9ffe5b69f1d473c903b07832008a942

Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on tumour location

Autor: Bernd Kasper, Olga Husson, Dide den Hollander, Winette T.A. Van der Graaf, Marco Fiore, Susanne Singer, Ingrid. M.E. Desar

Publikováno v: ESMO Open, Vol 5, Iss 5 (2020)

Patients with sarcoma experience many physical and psychological symptoms, adversely affecting their health-related quality of life (HRQoL). HRQoL assessment is challenging due to the diversity of the disease. This review aims to unravel the heteroge

Externí odkaz: https://doaj.org/article/545e60708ba34f55a61ca52645762e2a

Working to improve the management of sarcoma patients across Europe: a policy checklist

Autor: Bernd Kasper, Estelle Lecointe-Artzner, Suzanne Wait, Shannon Boldon, Roger Wilson, Alessandro Gronchi, Claudia Valverde, Mikael Eriksson, Sarah Dumont, Nora Drove, Athanasia Kanli, Markus Wartenberg

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)

Abstract Background The Sarcoma Policy Checklist was created by a multidisciplinary expert group to provide policymakers with priority areas to improve care for sarcoma patients. Main body This paper draws on this research, by looking more closely at

Externí odkaz: https://doaj.org/article/3dbce0a6e8904a1d8d32823dbb257453

Integrative genomic and transcriptomic analysis of leiomyosarcoma

Autor: Priya Chudasama, Sadaf S. Mughal, Mathijs A. Sanders, Daniel Hübschmann, Inn Chung, Katharina I. Deeg, Siao-Han Wong, Sophie Rabe, Mario Hlevnjak, Marc Zapatka, Aurélie Ernst, Kortine Kleinheinz, Matthias Schlesner, Lina Sieverling, Barbara Klink, Evelin Schröck, Remco M. Hoogenboezem, Bernd Kasper, Christoph E. Heilig, Gerlinde Egerer, Stephan Wolf, Christof von Kalle, Roland Eils, Albrecht Stenzinger, Wilko Weichert, Hanno Glimm, Stefan Gröschel, Hans-Georg Kopp, Georg Omlor, Burkhard Lehner, Sebastian Bauer, Simon Schimmack, Alexis Ulrich, Gunhild Mechtersheimer, Karsten Rippe, Benedikt Brors, Barbara Hutter, Marcus Renner, Peter Hohenberger, Claudia Scholl, Stefan Fröhling

Publikováno v: Nature Communications, Vol 9, Iss 1, Pp 1-15 (2018)

The molecular genetic landscape of leiomyosarcoma (LMS) is largely unknown. Here, the authors identify frequent DNA copy number alterations, whole-genome duplication, TP53 and RB1 inactivation, alternative telomere lengthening, and genomic imprints o

Externí odkaz: https://doaj.org/article/d4d8c497353f4a34a7f3673b1d82cb28

Community-driven development of a modified progression-free survival ratio for precision oncology

Autor: Sebastian Schölch, Benedikt Brors, Albrecht Stenzinger, Ursula Ehmer, Ulrich-Frank Pape, Christoph Springfeld, Dirk Jäger, Felix J Hüttner, Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Richard Schlenk, Hanno Glimm, Stefan Fröhling, Peter Horak, Leonidas Apostolidis, Marinela Augustin, Daniela Aust, Irfan Ahmed Bhatti, Johannes Bloehdorn, Cornelia Brendel, Christian Britschgi, Jan Braess, Stefan Burdach, Elena Busch, Jozefina Casuscelli, Alexander Desuki, Thomas Deutsch, Mareike Dietrich, Thomas J Ettrich, Johanna Falkenhorst, Tanja Fehm, Anne Flörcken, Andrea Forschner, Stefan Fuxius, Maria Gonzales-Carmona, Frank Griesinger, Sabine Grill, Stefan Gröschel, Georg Martin Haag, Ulrich Haag, Niels Halama, Holger Hebart, Nina Heidger, Barbara Hermes, Georg Hess, Simone Hettmer, Manuela Hoechstetter, Martin Hoffmann, Anna L Illert, Maximilian Jenzer, Bernd Kasper, Stefan Kasper-Virchow, Thomas Kindler, Ewa Koscielniak, Jan Krönke, Michael Kühn, Volker Kunzmann, Alois Lang, Jonas Leichsenring, Elisabeth Livingstone, Lucia Liotta, Kim Luley, Elisabeth Mack, Uwe M Martens, Klaus Metzeler, Jan Moritz Middeke, Lino Möhrmann, Roopa Jayarama-Naidu, Lukas Perkhofer, Arne Pfeufer, Constantin Pixberg, Michael Quante, Bernhard Rendenbach, Damian Rieke, Christian Rothermundt, Andre Norbert Sagerer, Martin Salzmann, Dieter Saur, Bastian Schilling, Jan Schleicher, Anke Schlenska-Lange, Thomas Schmidt, Sophia Schmitz, Rajiv Shah, Khalid Shoumariyeh, Alexander Siebenhüner, Martin Singh, Jens Siveke, Helen Starke, Sophia Strobel, Veronica Teleanu, Niklas Thon, Sebastian Wagner, Thomas Walle, Benedikt Westphalen, Bettina Whitlock, Eva Winkler, Naita Maren Wirsik, Lena Woydack, Angelika Zabel-du Bois, Stefanie Zschäbitz

Publikováno v: ESMO Open, Vol 4, Iss 6 (2019)

Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecul

Externí odkaz: https://doaj.org/article/0122f1ac148444cbaeb951db5af876a5